



Ref. No.P-66/2025-26/56
November 13, 2025

The Relationship Manager,
Department of Corporate Relations
BSE Limited,
P.J. Towers, Dalal Street
Fort, MUMBAI – 400 001

Subject: Outcome of Board Meeting held on Thursday, 13th November, 2025

Pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), we wish to inform you that, the Board of Directors of the Company at its Meeting held today i.e. 13th November, 2025, have inter-alia, considered and approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended on 30th September 2025 along with Statement of Assets and Liabilities as at 30th September 2025 (Standalone and Consolidated) and Statement of Cash Flow for the half year ended on 30th September 2025 (Standalone and Consolidated). The same has also been reviewed by the Audit Committee in its meeting held today.

Further, M/s Baheti & Co., Statutory Auditors of the Company have carried out the Limited Review of the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30th September 2025 and the Board has also taken on record their Limited Review Reports on the said Financial Results. A copy of the Limited Review Reports along with the Financial Results is enclosed herewith.

The aforesaid Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended on 30th September, 2025 will also be made available on the website of the Stock Exchanges i.e. www.bseindia.com and on the Company's website: www.kilpest.com

The meeting of the Board of Directors commenced at 3:00 p.m. and concluded at 4:40 p.m.

You are requested to take the same on record.

Thanking You,
For 3B BlackBio Dx Limited (Formerly, Kilpest India Limited)

**NIKHILKUBER
DUBEY**

Digitally signed by NIKHILKUBER
DUBEY
Date: 2025.11.13 16:47:12 +05'30'

Nikhil Kuber Dubey
Whole Time Director
DIN: 00538049

Encl: As above

M/s 3B BLACKBIO DX LTD
(Formerly M/s KILPEST INDIA LTD)
REGD.OFFICE: 7-C, INDUSTRIAL AREA, GOVINDPURA, BHOPAL-462 023
CIN:L24211MP1972PLC001131

Statement of Standalone Unaudited Financial Results for the Quarter and Half Year ended 30-09-2025

(Rs in lakhs)

S.No.	PARTICULARS	QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED
		30-09-2025 (unaudited)	30-06-2025 (unaudited)	30-09-2024 (unaudited)	30-09-2025 (unaudited)	30-09-2024 (unaudited)	31-03-2025 (AUDITED)
I	Revenue from operations	2791.16	2035.71	2657.19	4826.87	4407.88	9052.97
II	Other income	391.31	431.42	342.99	822.73	710.77	1502.58
III	Total Income (I + II)	3182.47	2467.13	3000.18	5649.60	5118.65	10555.55
IV	Expenses:						
	Cost of materials consumed	683.11	519.70	726.18	1202.81	1223.52	2475.73
	Purchases of Stock-in-Trade	0.00	0.00	0.00	0.00	0.00	0.00
	Changes in inventories of finished goods work-in-progress and Stock-in-Trade	6.42	(5.97)	13.40	0.45	(32.37)	(36.45)
	Employee benefits expenses	215.63	148.81	180.78	364.44	309.58	620.97
	Finance costs	1.20	0.80	3.48	2.00	4.10	9.68
	Depreciation and amortization expense	21.50	21.50	22.00	43.00	44.00	85.74
	Other expenses	302.27	214.35	227.47	516.62	363.69	1007.13
	Total expenses (IV)	1230.13	899.19	1173.31	2129.32	1912.52	4162.80
V	Profit/(loss) before exceptional items and tax (III - IV)	1952.34	1567.94	1826.87	3520.28	3206.13	6392.75
VI	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
VII	Profit before tax (V - VI)	1952.34	1567.94	1826.87	3520.28	3206.13	6392.75
VIII	Tax expense:						
	(1) Current tax	458.26	321.90	412.66	780.16	718.63	1484.57
	(2) Deferred tax	0.00	0.00	0.00	0.00	0.00	152.23
IX	Profit (Loss) for the period (VII-VIII)	1494.08	1246.04	1414.21	2740.12	2487.50	4755.95
X	Other Comprehensive Income/(loss)	0.00	0.00	0.00	0.00	0.00	0.00
XI	Total Comprehensive Income for the period (IX+X)	1494.08	1246.04	1414.21	2740.12	2487.50	4755.95
XII	Paid-up Equity Share capital	856.84	856.84	856.64	856.84	856.64	856.84
XIII	Reserve excluding Revaluation Reserves as per balance sheet of previous year	26421.76	26421.76	21921.24	26421.76	21921.24	21921.24
XIV	Earnings per equity share:						
	(1) Basic	17.44	14.54	16.51	31.98	29.04	55.51
	(2) Diluted	17.44	14.54	16.51	31.98	29.04	55.51

PLACE : BHOPAL
DATE: 13/11/2025



FOR AND ON BEHALF OF THE BOARD

(Signature)
NIKHIL KUBER DUBEY
WHOLE TIME DIRECTOR
DIN:00538049

M/s 3B BLACKBIO DX LTD
(Formerly M/s KILPEST INDIA LTD)
REGD.OFFICE: 7-C, INDUSTRIAL AREA, GOVINDPURA, BHOPAL-462 023
CIN:L24211MP1972PLC001131

STANDALONE UNAUDITED STATEMENT OF CASH FLOW FOR THE HALF YEAR ENDED 30th SEPTEMBER 2025
(Rs. in Lakhs)

PARTICULARS	For the half year ended 30th Sept 2025	For the year ended 31st March 2025
	Un-Audited	Audited
A CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit Before Tax & Extra-Ordinary Items	3520.28	6392.75
Adjustments for:		
Profit on sale of Fixet Assets	0.00	0.00
Depreciation	43.00	85.74
Interest Paid	2.00	9.68
Unrealised Gain on Investments carried at Fair Value through P&L	(360.23)	(605.91)
Operating Profit before working capital changes	3205.05	5882.26
Adjustments for:		
Inventories	48.61	(16.89)
Trade and other Receivables	(69.19)	(53.38)
Trade Payables and Other Liabilities	(788.06)	119.17
Cash generated from operations	2396.41	5931.16
Income tax payments	(780.16)	(1484.57)
Net Cash used/ available from Operating Activities (A)	1616.25	4446.59
B CASH FLOW FROM INVESTING ACTIVITIES		
Purchase / Sale of Fixed Assets	(73.92)	(69.77)
Acquisition of Investment (Net of Sales)	(1576.47)	(3294.20)
Decrease in other non current assets	(415.46)	(0.02)
Net Cash Used in Investing Activities (B)	(2065.85)	(3363.99)
C CASH FLOW FROM FINANCING ACTIVITIES		
Increase in share capital	0.00	0.00
Capital Subsidy Received	33.54	
Increase/Decrease in bank borrowings	9.59	0.00
Decrease in Other Non Current Liability	0.00	(40.75)
Increase/Decrease in other borrowings	(14.12)	0.00
Interest Paid	(2.00)	(9.68)
Equity Dividend Paid	(342.24)	(256.65)
Net Cash From Financing activities (C)	(315.23)	(307.08)
Net Increase /Decrease in Cash & Cash equivalents (A+B+C)	(764.83)	775.52
Cash & Cash equivalents as at 1st April opening balance	6263.35	5487.83
Cash & Cash equivalents as at 30th Sept closing balance	5498.52	6263.35

PLACE : BHOPAL
DATE: 13/11/2025



FOR AND ON BEHALF OF THE BOARD

(Signature)
NIKHIL KUBER DUBEY
WHOLE TIME DIRECTOR
DIN:00538049

M/s 3B BLACKBIO DX LTD
(Formerly M/s KILPEST INDIA LTD)
REGD.OFFICE: 7-C, INDUSTRIAL AREA, GOVINDPURA, BHOPAL-462 023
CIN:L24211MP1972PLC001131

Standalone UnAudited Balance Sheet As On 30-09-2025

(Rs. in Lakhs)

PARTICULARS	STANDALONE	
	As at 30-09-2025 Un-Audited	As at 31-03-2025 Audited
ASSETS		
Non-current assets		
(a) Property, Plant and Equipment	667.98	637.06
(b) Capital work-in-progress	0.00	0.00
(c) Investment Property	0.00	0.00
(d) Goodwill	0.00	0.00
(e) Other Intangible assets	0.00	0.00
(f) Intangible assets under development	0.00	0.00
(g) Biological Assets other than bearer plants	0.00	0.00
(h) Financial Assets	0.00	0.00
(i) Investments	18606.70	16670.00
(ii) Trade receivables	0.00	0.00
(iii) Loans	415.46	0.00
(i) Deferred tax assets (net)	0.00	0.00
(j) Other non-current assets	0.00	0.00
Current assets		
(a) Inventories	765.27	813.88
(b) Financial Assets	0.00	0.00
(i) Investments	0.00	0.00
(ii) Trade receivables	4149.23	3518.25
(iii) Cash and cash equivalents	561.70	627.42
(iv) Bank balances other than (iii) above	4936.82	5635.93
(v) Other Financial Assets	18.53	20.49
(vi) Loans	0.00	0.00
(vii) Others (to be specified)	0.00	0.00
(c) Current Tax Assets (Net)	0.00	0.00
(d) Other current assets	1229.18	1789.01
Total Assets	31350.87	29712.04
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share capital	856.84	856.84
(b) Other Equity		
Equity Attributable to Owners of the Co.	28853.18	26421.76
Non-Controlling Interest	0.00	0.00
LIABILITIES		
Non-current liabilities		
(a) Financial Liabilities	0.00	0.00
(i) Borrowings	16.57	30.69
(ii) Trade payables	0.00	0.00
(iii) Other financial liabilities (other than those specified in item (b), to be specified)	0.00	0.00
(b) Provisions	0.00	0.00
(c) Deferred tax liabilities (Net)	581.84	581.84
(d) Other non-current liabilities	0.00	0.00
Current liabilities		
(a) Financial Liabilities		
(i) Borrowings	9.59	0.00
(ii) Trade payables		
Total outstanding dues of micro enterprises and small enterprises	3.67	61.93
Total outstanding dues of creditors other than micro enterprises and small enterprises	8.39	96.76
(iii) Other financial liabilities (other than those specified in item (c))	46.83	37.24
(b) Other current liabilities	193.80	142.98
(c) Provisions	780.16	1482.00
(d) Current Tax Liabilities (Net)	0.00	0.00
Total Equity and Liabilities	31350.87	29712.04

PLACE : BHOPAL
DATE: 13/11/2025



FOR AND ON BEHALF OF THE BOARD

(Signature)
NIKHIL KUBER DUBEY
WHOLE TIME DIRECTOR
DIN:00538049



3B BlackBio Dx Ltd.

NOTES ON STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF-YEAR ENDED 30th SEPTEMBER, 2025

1. The above results are as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended and have been taken on record by the Board of Directors at its meeting held on November 13, 2025 after being reviewed by the Audit Committee.
2. The Company's Agrochemical Business is seasonal in nature and the performance can be impacted by weather conditions and cropping pattern.
3. These financial results have been prepared in accordance with the requirements of Indian Accounting Standards (Ind AS) as prescribed under section 133 of Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules, 2015 as amended.
4. All the figures of financials have been rounded off to nearest lakh in rupees.
5. Previous period/Year figures have been regrouped / rearranged, wherever deemed necessary.
6. The results of the company are available for investors at www.kilpest.com and www.bseindia.com.
7. Other expenses for the quarter ended September 30, 2025 includes one-time expenses paid to consultants towards fees for M&A advisory and Due Diligence amounting to Rs 54.54 lacs, incurred for the acquisition of Coris Bioconcept SRL, Belgium. Total amount for Half-Yearly Period paid under this head is Rs 138.46 lac.

Limited Review:


The Limited Review, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, has been completed and the related Report shall be forwarded to the Stock Exchanges. This Report does not have any impact on the above "Results and Notes" for the quarter and half year ended September 30, 2025 which needs to be explained.

PLACE: BHOPAL
DATE: 13/11/2025



FOR AND ON BEHALF OF THE BOARD

NIKHIL KUBER DUBEY
WHOLE TIME DIRECTOR
DIN: 00538049



BAHETI & CO.
CHARTERED ACCOUNTANTS
24, M.P. NAGAR ZONE II
BHOPAL 462011
2763141, 4251535

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
3B BlackBio Dx Limited (Formerly, Kilpest India Limited)

1. We have reviewed the accompanying statement of unaudited standalone financial results of 3B BlackBio Dx Limited (Formerly, Kilpest India Limited) (the "Company") for the quarter ended September 30, 2025 and year to date from April 1, 2025 to September 30, 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS')



specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement

For BAHETI & CO.
Chartered Accountants
(Firm Registration No 006287C)



(DEEPAK BAHETI)
Partner



Place: Bhopal
Date: 13/11/2025

Membership No: 075063

UDIN: 25075063BMGYOQ8692

M/s 3B BLACKBIO DX LTD
(Formerly M/s KILPEST INDIA LTD)
REGD.OFFICE: 7-C, INDUSTRIAL AREA, GOVINDPURA, BHOPAL-462 023
CIN:L24211MP1972PLC001131

Statement of Consolidated Unaudited Financial Results for the Quarter and Half Year ended 30-09-2025

(Rs in lakhs)

S.No.	PARTICULARS	QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED
		30-09-2025	30-06-2025	30-09-2024	30-09-2025	30-09-2024	31-03-2025
		(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(AUDITED)
I	Revenue from operations	3390.21	2223.46	2914.70	5613.67	4858.10	9646.86
II	Other income	550.59	431.66	343.65	982.25	712.75	1508.36
III	Total Income (I + II)	3940.80	2655.12	3258.35	6595.92	5570.85	11155.22
IV	Expenses:						
	Cost of materials consumed	918.76	561.92	751.14	1480.68	1263.12	2601.02
	Purchases of Stock-in-Trade	0.00	0.00	0.00	0.00	0.00	0.00
	Changes in inventories of finished goods work-in-progress and Stock-in-Trade	6.42	(5.97)	13.40	0.45	(32.37)	(36.45)
	Employee benefits expenses	462.79	176.54	208.38	639.33	370.53	732.08
	Finance costs	3.53	1.05	3.48	4.58	4.10	10.85
	Depreciation and amortization expense	58.20	27.67	27.11	85.87	53.91	108.59
	Other expenses	529.08	307.56	324.27	836.64	545.26	1339.31
	Total expenses (IV)	1978.78	1068.77	1327.78	3047.55	2204.55	4755.40
V	Profit/(loss) before exceptional items and tax (III - IV)	1962.02	1586.35	1930.57	3548.37	3366.30	6399.82
VI	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
VII	Profit before tax (V - VI)	1962.02	1586.35	1930.57	3548.37	3366.30	6399.82
VIII	Tax expense:						
	(1) Current tax	458.26	321.90	444.29	780.16	750.26	1478.47
	(2) Deferred tax	0.00	0.00	0.00	0.00	0.00	152.24
IX	Profit (Loss) for the period (VII-VIII)	1503.76	1264.45	1486.28	2768.21	2616.04	4769.11
	Profit or loss, attributable to owners of parent	1471.19	1258.93	1464.66	2730.12	2577.48	4765.17
	Total profit or loss, attributable to non-controlling interests	32.57	5.52	21.62	38.09	38.56	3.95
X	Other Comprehensive Income/(loss)	0.00	0.00	0.00	0.00	0.00	0.00
XI	Total Comprehensive Income for the period (IX+X)	1503.76	1264.45	1486.28	2768.21	2616.04	4769.11
	Profit or loss, attributable to owners of parent	1471.19	1258.93	1464.66	2730.12	2577.48	4765.17
	Total profit or loss, attributable to non-controlling interests	32.57	5.52	21.62	38.09	38.56	3.95
XII	Paid-up Equity Share capital	856.84	856.84	856.64	856.84	856.64	856.84
XIII	Reserve excluding Revaluation Reserves as per balance sheet of previous year	26243.65	26243.65	21690.58	26243.65	21690.58	21690.58
XIV	Earnings per equity share:						
	(1) Basic	17.55	14.76	17.35	32.31	30.54	55.66
	(2) Diluted	17.55	14.76	17.35	32.31	30.54	55.66

PLACE : BHOPAL
DATE: 13/11/2025



FOR AND ON BEHALF OF THE BOARD

(Signature)
NIKHIL KUBER DUBEY
WHOLE TIME DIRECTOR
DIN:00538049

M/s 3B BLACKBIO DX LTD
(Formerly M/s KILPEST INDIA LTD)
REGD.OFFICE: 7-C, INDUSTRIAL AREA, GOVINDPURA, BHOPAL-462 023
CIN:L24211MP1972PLC001131

CONSOLIDATED UNAUDITED STATEMENT OF CASH FLOW FOR THE HALF YEAR ENDED 30th SEPTEMBER 2025

(Rs in lakhs)

PARTICULARS	For the half year ended 30th Sept 2025	For the year ended 31st March 2025
	Un-Audited	Audited
A CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit Before Tax & Extra-Ordinary Items	3548.37	6399.82
Adjustments for:		
Depreciation	85.87	108.59
Interest Paid	4.58	10.85
Unrealised Gain on Investments carried at Fair Value through P&L	(360.23)	(605.91)
Operating Profit before working capital changes	3278.59	5913.35
Adjustments for:		
Inventories	(212.58)	(31.46)
Trade and other Receivables	(373.31)	(179.51)
Trade Payables and Other Liabilities	(660.35)	111.73
Cash generated from operations	2032.35	5814.11
Income tax payments	(780.16)	(1478.47)
Net Cash used/ available from Operating Activities (A)	1252.19	4335.64
B CASH FLOW FROM INVESTING ACTIVITIES		
Purchase / Sale of Fixed Assets	(116.85)	(90.39)
Acquisition of a subsidiary, net of cash acquired	(718.93)	0.00
Acquisition of Investment (Net of Sales)	206.17	(3294.20)
Decrease in other non current assets	0.04	(0.02)
Net Cash Used in Investing Activities (B)	(629.57)	(3384.61)
C CASH FLOW FROM FINANCING ACTIVITIES		
Increase in share capital	0.00	0.00
Capital Subsidy Received	33.54	0.00
Increase/Decrease in bank borrowings	9.59	(6.32)
Decrease in other borrowings	(14.12)	(48.11)
Decrease/Increase in Other Non Current Liability	7.96	0.00
Interest Paid	(4.58)	(10.85)
Equity Dividend Paid	(342.24)	(256.65)
Net Cash From Financing activities (C)	(309.85)	(321.93)
Net Increase /Decrease in Cash & Cash equivalents (A+B+C)	312.77	629.10
Cash & Cash equivalents as at 1st April opening balance	6883.22	6214.72
Exchange difference on translation of foreign currency cash & cash equivalents	17.50	39.40
Cash & Cash equivalents as at 30th Sept closing balance	7213.49	6883.22

FOR AND ON BEHALF OF THE BOARD

PLACE : BHOPAL
DATE: 13/11/2025



(Signature)
NIKHIL KUBER DUBEY
WHOLE TIME DIRECTOR
DIN:00538049

M/s 3B BLACKBIO DX LTD
(Formerly M/s KILPEST INDIA LTD)
REGD.OFFICE: 7-C, INDUSTRIAL AREA, GOVINDPURA, BHOPAL-462 023
CIN:L24211MP1972PLC001131

Consolidated UnAudited Balance Sheet as on 30-09-2025 (Rs. in Lakhs)

PARTICULARS	CONSOLIDATED	
	As at 30-09-2025 Un-Audited	As at 31-03-2025 Audited
ASSETS		
Non-current assets		
(a) Property, Plant and Equipment	1725.30	721.86
(b) Capital work-in-progress	0.00	0.00
(c) Investment Property	0.00	0.00
(d) Goodwill	0.00	0.00
(e) Other Intangible assets	0.00	0.00
(f) Intangible assets under development	0.00	0.00
(g) Biological Assets other than bearer plants	0.00	0.00
(h) Financial Assets	0.00	0.00
(i) Investments	16016.03	15631.02
(ii) Trade receivables	0.00	0.00
(iii) Loans	0.00	0.00
(i) Deferred tax assets (net)	0.00	0.00
(j).Other non-current assets	2.44	0.00
Current assets		
(a) Inventories	2292.72	874.20
(b) Financial Assets	0.00	0.00
(i) Investments	0.00	0.00
(ii) Trade receivables	5046.97	3652.04
(iii) Cash and cash equivalents	2276.67	1247.28
(iv) Bank balances other than (iii) above	4936.82	5635.94
(v) Other Financial Assets	18.53	20.49
(vi) Loans	0.00	0.00
(vii) Others (to be specified)	0.00	0.00
(c) Current Tax Assets (Net)	0.00	0.00
(d) Other current assets	1767.52	1789.01
Total Assets	34083.00	29571.84
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share capital	856.84	856.84
(b) Other Equity		
Equity Attributable to Owners of the Co.	28965.11	25985.39
Non-Controlling Interest	574.24	258.26
LIABILITIES		
Non-current liabilities		
(a) Financial Liabilities		
(i) Borrowings	16.57	30.69
(ii) Trade payables	0.00	0.00
(iii) Other financial liabilities (other than those specified in item (b), to be specified)	0.00	0.00
(b) Provisions	0.00	0.00
(c) Deferred tax liabilities (Net)	581.84	581.84
(d) Other non-current liabilities	474.40	0.00
Current liabilities		
(a) Financial Liabilities	0.00	0.00
(i) Borrowings	9.59	0.00
(ii) Trade payables		
Total outstanding dues of micro enterprises and small enterprises	3.67	61.93
Total outstanding dues of creditors other than micro enterprises and small enterprises	512.46	134.66
(iii) Other financial liabilities (other than those specified in item (c))	46.83	37.24
(b) Other current liabilities	1261.29	142.99
(c) Provisions	780.16	1482.00
(d) Current Tax Liabilities (Net)	0.00	0.00
Total Equity and Liabilities	34083.00	29571.84

PLACE : BHOPAL
DATE: 13/11/2025



FOR AND ON BEHALF OF THE BOARD

Nikhil Kuber Dubey
NIKHIL KUBER DUBEY
WHOLE TIME DIRECTOR
DIN:00538049

**NOTES ON CONSOLIDATED UN-AUDITED FINANCIAL RESULT FOR THE QUARTER AND HALF-YEAR ENDED 30th SEPTEMBER, 2025**

1. The above results are as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended and have been taken on record by the Board of Directors at its meeting held on November 13, 2025 after being reviewed by the Audit Committee.
2. These financial results have been prepared in accordance with the requirements of Indian Accounting Standards (Ind AS) as prescribed under section 133 of Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules, 2015 as amended;
3. The Company has two identified Reportable Business Segments namely Agrochemical and Molecular Diagnostic Kits (Health Care Sector)
4. During the quarter, the company along with its subsidiary had signed the definitive agreement to acquire shares of Coris Holding SRL and all closing conditions related to the purchase of the entire issued share capital of Coris Holding SRL (holding company of Coris Bioconcept SRL) from Avacta Group Plc, London were satisfied and the completion of the purchase took place on Friday August 29, 2025. Therefore, Coris Holding SRL has been considered for the purpose of consolidation for the quarter and half year ended 30th September, 2025. Figures of Coris has been taken for the period from 29-08-2025 (date of acquisition) to 30-09-2025.
5. The summarized figures for M/s 3B BLACKBIO DX LIMITED (FORMERLY, KILPEST INDIA LIMITED) (Both Agrochemicals and Diagnostic Division) as a standalone entity are:

PARTICULARS	QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED
	30-09-2025	30-06-2025	30-09-2024	30-09-2025	30-09-2024	31-03-2025
	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(AUDITED)
Total Income (Rs Lakhs)	3182.47	2467.13	3000.18	5649.60	5118.65	10555.55
Profit Before Tax (Rs Lakhs)	1952.34	1567.94	1826.87	3520.28	3206.13	6392.75
Profit After Tax (Rs Lakhs)	1494.08	1246.04	1414.21	2740.12	2487.50	4755.95
Basic Earnings Per Share (Rs)	17.44	14.54	16.51	31.98	29.04	55.51

6. The Consolidated Financials include the Financials of Subsidiary Company also.
7. All the figures of financials have been rounded off to nearest lakh in rupees.
8. Previous period/Year figures have been regrouped / rearranged, wherever deemed necessary.





3B BlackBio Dx Ltd.
(Formerly - Kilpest India Limited)

9. The Results of the Company are available for investors at www.kilpest.com and www.bseindia.com

Limited Review:

The Limited Review, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, has been completed and the related Report shall be forwarded to the Stock Exchanges. This Report does not have any impact on the above "Results and Notes" for the quarter ended September 30, 2024 which needs to be explained.

FOR AND ON BEHALF OF THE BOARD

PLACE: BHOPAL
DATE: 13/11/2025



NIKHIL KUBER DUBEY
WHOLE TIME DIRECTOR
DIN: 00538049



BAHETI & CO.
CHARTERED ACCOUNTANTS
24, M.P. NAGAR ZONE II
BHOPAL 462011
2763141,4251535

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
3B BlackBio Dx Limited (Formerly, Kilpest India Limited)

We have reviewed the accompanying Statement of unaudited consolidated financial results of 3B BlackBio Dx Limited (Formerly, Kilpest India Limited) (hereinafter referred to as 'the Holding Company'), its subsidiary (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter ended September 30, 2025 and year to date from April 1, 2025 to September 30, 2025 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



We also performed procedures in accordance with the Master Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

The Statement includes the results of the following entities:

- i. 3B BlackBio Dx Limited (Formerly, Kilpest India Limited, Holding)
- ii. TRUPCR Europe Limited (Subsidiary)
- iii. Coris Holding SRL, Belgium

Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

The unaudited interim financial results and other unaudited financial information of the subsidiary has not been reviewed by their auditor and have been approved and furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the affairs of these subsidiaries, are based solely on such unaudited interim financial results and other unaudited financial information. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Bhopal
Date: 13/11/2025

For BAHETI & CO.
(FRN 006287C)
Chartered Accountants



(DEEPAK BAHETI)
Partner



Membership No.075063

UDIN 25075063BMGYOR1951

M/s 3B BLACKBIO DX LTD
(Formerly M/s KILPEST INDIA LTD)
REGD.OFFICE: 7-C, INDUSTRIAL AREA, GOVINDPURA, BHOPAL-462 023
CIN:L24211MP1972PLC001131

CONSOLIDATED SEGMENTWISE

REVENUE AND RESULTS

(Rs. in Lakhs)

	Quarter ended 30-09-2025 Unaudited	Quarter ended 30-06-2025 Unaudited	Quarter ended 30-09-2024 Unaudited	Half Year ended 30-09-2025 Unaudited	Half Year ended 30-09-2024 Unaudited	Year ended 31-03-2025 Audited
1 Segment Revenue						
(a) Agrochemicals	347.38	227.40	457.15	574.78	706.11	1218.61
(b) Diagnostic kits	3042.83	1996.06	2457.55	5038.89	4151.99	8428.25
Total income from operations (net)	3390.21	2223.46	2914.70	5613.67	4858.10	9646.86
2 Segment Results						
(a) Agrochemicals	27.22	(4.36)	31.99	22.86	29.61	(9.84)
(b) Diagnostic kits	1938.32	1591.77	1902.06	3530.09	3340.79	6420.50
Total Segment Profit before Interest and Tax	1965.55	1587.40	1934.05	3552.95	3370.40	6410.66
Less : Interest Expense						
(a) Agrochemicals	1.21	0.79	3.48	2.00	4.10	9.68
(b) Diagnostic kits	2.32	0.26	0.00	2.58	0.00	1.17
Profit before Tax	1962.02	1586.35	1930.57	3548.37	3366.30	6399.81
3 Segment Assets						
(a) Agrochemicals	2790.51	2888.30	2873.37	2790.51	2873.37	2718.56
(b) Diagnostic kits	31292.49	26798.45	24383.92	31292.49	24383.92	26853.28
Total Segment Assets	34083.00	29686.75	27257.29	34083.00	27257.29	29571.84
4 Segment Liabilities						
(a) Agrochemicals	243.51	400.86	446.13	243.51	446.13	225.96
(b) Diagnostic kits	3443.30	920.95	1397.33	3443.30	1397.33	2245.39
Total Segment Liabilities	3686.81	1321.81	1843.46	3686.81	1843.46	2471.35
(a) Agrochemicals	2547.00	2487.44	2427.24	2547.00	2427.24	2492.60
(b) Diagnostic kits	27849.19	25877.50	22986.59	27849.19	22986.59	24607.89
5 Capital Employed	30396.19	28364.94	25413.83	30396.19	25413.83	27100.49

FOR AND ON BEHALF OF THE BOARD



(Signature)
NIKHIL KUBER DUBEY
WHOLE TIME DIRECTOR
DIN:00538049

PLACE : BHOPAL
DATE: 13/11/2025